Mabion to Fulfill CDMO Orders for a New Client – IBMP

Mabion S.A. (“Mabion”), a leading Polish CDMO specializing in the development and manufacturing of biopharmaceuticals for third parties, and Instituto de Biologia Molecular do Paraná (“IBMP”), a Scientific and Technological Institution (ICT) and a supplier of quality products to the Brazilian health network, are proud to announce a strategic cooperation agreement to develop a biosimilar.

Under the agreement, Mabion will be responsible for the full development of a stable and robust bioprocess; next, scaling it up to a commercial manufacturing scale and followed by transferring the process to GMP conditions. Mabion will manufacture GMP drug substance for IBMP to support their clinical trials. This work represents an important step in enabling IBMP to secure a supply of biosimilar therapeutics for the Brazilian market. Development efforts will include close collaboration with Sartorius as Mabion’s strategic partner, specifically leveraging its core expertise in cell line development. This cooperation agreement will also kickstart the recently signed partnership agreement between Mabion and Sartorius.

Dr. Pedro Ribeiro Barbosa, CEO of IBMP, stated: “The biosimilar project is the first of its kind in our pipeline. Due to the complex nature of the molecule and its importance, we have made every effort to identify trustworthy partners for its execution. We strongly believe that the combined expertise of Mabion and Sartorius will enable us to achieve our goals seamlessly.”

Krzysztof Kaczmarczyk, CEO of Mabion, commented: “This contract exemplifies the consistent implementation of our strategy to become a leading player in the biologics CDMO industry. We are proud that our knowledge, experience, and flexibility have been positively evaluated by our client, who has entrusted us with the execution of this crucial project. We are confident this marks the beginning of a long-term and mutually rewarding partnership.”

The total value of the first Statement of Work (SOW) will amount to approximately PLN 18.3 million. Payments, denominated in USD, will be made systematically over 14 months, with services scheduled to begin in the second quarter of 2025.

This cooperation aligns with Mabion’s strategy to strengthen its position as a leading Contract Development and Manufacturing Organization (CDMO). It also marks the formal commencement of Mabion’s collaboration with Sartorius as a strategic partner, enhancing the comprehensiveness of services offered.

About IBMP

IBMP established in 1999 through a partnership between the Oswaldo Cruz Foundation and the Government of Paraná, has grown into a prominent Scientific and Technological Institution (ICT). It supports the advancement of science and technology in Brazil and provides safe, high-quality healthcare products to the public health network. The institute boasts a GMP-certified infrastructure for developing healthcare supplies and a highly skilled team of over 50 masters and doctors. Its portfolio includes molecular and rapid diagnostic tests tailored to Brazil’s epidemiological needs, serving both public and private sectors. In addition to its product offerings, the institute engages in collaborative research and innovation projects with national and international partners, furthering scientific and technological progress globally. Committed to life and society, the institute emphasizes responsibility and dedication in all its endeavors.

About Mabion S.A.

Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007 originally as a biosimilar developer, which in recent years has transformed into a fully integrated biologics contract development and manufacturing organization (CDMO).  Mabion only focuses on providing a broad spectrum of services to its clients in the segment of small and medium-sized biopharmaceutical projects at various stages of development (from the process development stage to commercial manufacturing). Mabion’s competencies include protein production using mammalian and insect cell cultures, protein purification, GMP-standard manufacturing activities (obtaining Active Substances “Drug Substance” and Finished Products “Drug Product”), development of analytical tools (for structural, functional, and physicochemical characterization) and clinical development. Mabion’s mission is to establish itself as a recognizable player in the global biologics contract manufacturing and contract drug development market. Mabion is a public company listed on the Warsaw Exchange.

Mabion contact for media and individual investors:

Michał Wierzchowski
+48 531 613 067
+48 22 440 14 40
michal.wierzchowski@ccgroup.pl

Mardoniusz Maćkowiak           
+48 605 959 539
+48 22 440 14 40
mardoniusz.mackowiak@ccgroup.pl

Mabion contact for institutional investors and analysts:

Piotr Owdziej
+48 697 612 913
+48 22 440 14 40
piotr.owdziej@ccgroup.pl

Katarzyna Mucha
+48 697 613 712
+48 22 440 14 40
katarzyna.mucha@ccgroup.pl